Spirair

Executive Summary

Spirair is a San Francisco-based medical device company developing bioabsorbable implants for minimally invasive treatment of nasal septal deviation and turbinate hypertrophy, two common causes of nasal obstruction. Founded in 2019, the company aims to address the limitations of current surgical options by offering a simpler, less invasive procedure that preserves tissue and integrates into existing ENT workflows. The global ENT device market is sizable, with significant demand for office-based, quick-recovery solutions. Spirair's technology has the potential to improve patient outcomes and reduce procedure time, positioning the company for growth if clinical validation is successful. As a private, early-stage firm with no disclosed funding, Spirair likely relies on grants or angel investments; its next milestones will be critical for attracting Series A capital and advancing toward commercialization.

Upcoming Catalysts (preview)

• Q2 2026Initiation of pivotal clinical trial for septal deviation implant60% success
• Q4 2026FDA 510(k) clearance or Breakthrough Device designation50% success
• 2027Strategic partnership with major ENT device distributor40% success